Regarding caspase targeting agents, the pan-caspase inhibitor Emricasan (EMR) was shown to attenuate caspase-1 hyperactivity in CD4+ T cells from COVID-19 patients ex vivo (43) and the caspase-8 inhibitor Z-IETD-FMK subdued SARS-CoV-2-induced BID cleavage and caspase-3 activation (41). This evidence concerns the gene CD4 and COVID-19.